Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Fineline Cube May 24, 2026
Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Fineline Cube May 24, 2026
Hospital

Hainan’s First Integrated Bladder Cancer Center Launched at Provincial Urology Meeting

Fineline Cube Dec 6, 2022

The first Integrated Bladder Cancer Center (IBCC) in Hainan province was inaugurated in Hainan General...

Deals Hospital

United Family Healthcare Partners with HSS for Orthopedic Collaboration

Fineline Cube Dec 6, 2022

United Family Healthcare (UFH), a private comprehensive medical institution based in Beijing, announced an agreement...

Company Medical Device

MicroPort MedBot’s Orthopedic Surgery Robot Receives CE Certification

Fineline Cube Dec 6, 2022

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced receiving a CE certification in Europe...

Company Drug

Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers

Fineline Cube Dec 6, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...

Company Deals

Akeso Biopharma Plans IPO on Shanghai’s STAR Market

Fineline Cube Dec 6, 2022

China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...

Company

Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups

Fineline Cube Dec 6, 2022

Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners...

Company Deals

Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets

Fineline Cube Dec 6, 2022

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...

Company Drug

WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China

Fineline Cube Dec 5, 2022

Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells)...

Company Drug

Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study

Fineline Cube Dec 5, 2022

China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...

Company Deals Digital

China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma

Fineline Cube Dec 5, 2022

China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot...

Company Drug

Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study

Fineline Cube Dec 5, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...

Company Drug

Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Included in China’s Emergency Use Program

Fineline Cube Dec 5, 2022

China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced the inclusion of its COVID-19 vaccine...

Company Medical Device

Microport EP Medtech’s Pressure Monitoring Catheter Approved by NMPA

Fineline Cube Dec 5, 2022

Shanghai Microport EP Medtech Co., Ltd’s disposable pressure monitoring magnetic positioning radiofrequency catheter has been...

Company Drug

Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China

Fineline Cube Dec 5, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...

Company Drug

Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia

Fineline Cube Dec 5, 2022

A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...

Company Drug

Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx

Fineline Cube Dec 5, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...

Company Drug

Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program

Fineline Cube Dec 5, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...

Company Drug

Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003

Fineline Cube Dec 5, 2022

China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...

Company Deals

Lavamed Secures USD 40M in Angel and Series A Financing Rounds

Fineline Cube Dec 5, 2022

Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...

Company Drug

Innovent Biologics Doses First Volunteer in Orismilast Phase I Study

Fineline Cube Dec 5, 2022

China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...

Posts pagination

1 … 595 596 597 … 670

Recent updates

  • Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma
  • Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer
  • Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors
  • Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026
  • Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2/QX001S in Crohn’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Company Drug

Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors

Company Drug

Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.